Dossier assessment

Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V

Status
Status: Commission completed
Project no.
A23-110
Last updated

Report documents

  1. Extract of dossier assessment

    Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 514 kB, EN, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-110_en
  2. Dossier assessment

    Midostaurin (acute myeloid leukaemia) – Benefit assessment according to §35a Social Code Book V

    published on
    Document type
    PDF document, 740 kB, DE, not accessible
    DOI-Link
    https://doi.org/10.60584/A23-110

Dossier assessment

Indication:

In combination with standard daunorubicin and cytarabine induction and high-dose cytarabine consolidation chemotherapy, and for patients in complete response followed by midostaurin single agent maintenance therapy, for adult patients with newly diagnosed acute myeloid leukaemia who are FMS-like tyrosine kinase 3 mutation-positive

Result of dossier assessment:

Added benefit not proven

Additional information

Federal Joint Committee (G-BA)

2024-05-02 A G-BA decision was published.

G-BA documents on this decision

Project details

Project no.
A23-110
Commission
Commission awarded on 14.12.2023 by the Federal Joint Committee (GBA).
Report type
Dossier assessment
Status
Commission completed
Department/Division
Drug Assessment
Topic
Cancer
Note

After completion of the assessment by IQWiG the Federal Joint Committee (GBA) conducts a commenting procedure. This may provide supplementary information and as a result lead to a modified benefit assessment. Further information and the decision on the early benefit assessment can be found on the relevant page of the GBA website.

DOI

https://doi.org/10.60584/A23-110_en

Connected Projects

  1. Dossier assessment

    Midostaurin (systemic mastocytosis) – Benefit assessment according to §35a Social Code Book V

    Project no.
    A23-111
    Last updated

    Status: Commission completed

  2. Addendum

    Midostaurin (acute myeloid leukaemia) – Addendum to Project A23-110

    Project no.
    A24-34
    Last updated

    Status: Commission completed

Contact

Info Service (German)

Subscribe to daily updated information on projects, calls for tender, current vacancies and events as well as our press releases.

Register

Contact form

Questions about commissions, publications and press releases can be sent to us via this form.

Contact form